Symbiotec Pharmalab Limited disclosed the transcript of its Q1 FY27 Earnings Conference Call, held on Tuesday, September 22, 2026. The event was an earnings call and investor interaction hosted by JM Financials to discuss the company's operational and financial performance for the first quarter of fiscal year 2027.

The management participants included:

  • Mr. Anil Satwani – Chairman and Managing Director
  • Mr. Raghavender Ramachandran – Chief Financial Officer
  • Mr. Shubham Saboo – MD's Office
  • Mr. Kapil Mishra – MD's Office
  • Mr. Prakash Sawlani – Director SGA, Investor Relation Advisor

The call was moderated by Mr. Gourav Bhama from JM Financials. The company stated that the transcript was being made available on the company's website www.symbiotec.com as part of its regulatory compliance under SEBI LODR Regulations.

The management provided a comprehensive business update covering three verticals:

1. API Business (Current Core Business):

  • Contributed INR 215 crores in Q1 FY27 revenue (6% YoY growth)
  • Maintains strong gross margins of 60%+
  • EBITDA of INR 66 crores (9% YoY growth)
  • Recently completed US FDA audit at Pithampur site (August 2026) with responses submitted
  • Serves over 200 customers across 40+ countries
  • 70% of FY26 revenues from customers served for over 7 years

2. Biotech CDMO Services (New Business):

  • Multiple contracts secured: 5-year take-or-pay for insulin drug substance; 10-year take-or-pay with US-based alternate protein company; term sheet with European alternate protein company
  • Ujjain facility commissioned with 400 kL fermentation capacity
  • Expected revenue commencement in next 6-12 months

3. Complex Injectables (New Business - Forward Integration):

  • First ANDA filed for Double Chamber Vial (DCV) product in September 2026
  • Second molecule ANDA filing scheduled for Q4 FY27
  • Term sheet signed with large US pharmaceutical multinational in August 2026
  • Definitive agreement expected to be signed in early Q3 FY27

The company provided FY27 guidance with high confidence:

  • Targeting 20% revenue growth
  • Targeting 25% EBITDA growth
  • Plus-minus 5% possible due to global operating environment uncertainties

Financial highlights for Q1 FY27:

  • Consolidated revenue: INR 218 crores (7% YoY growth)
  • Consolidated EBITDA: INR 45 crores
  • Net profit: INR 14 crores
  • Net debt position as of June 30: INR 398 crores
  • Post-IPO net debt (after INR 142 crores net proceeds): ~INR 326 crores
  • Q1 FY27 capex: INR 68 crores

The company noted that current earnings include INR 23 crores operating expenses and INR 11 crores depreciation from new businesses without corresponding revenues, creating a drag on profitability. This drag is expected to continue for the next 2-3 quarters but will be offset by milestone revenues in H2 FY27.

Capex outlook indicates INR 200-250 crores annually for the next 2-3 years, with potential for acceleration based on contract visibility. The company has invested INR 1,000+ crores in new facilities (biotech CDMO and injectables) which are expected to start generating revenues in the next 6-12 months.

Additional Notes Section

The disclosure included the full transcript of the earnings conference call containing management commentary and Q&A with analysts. The document explicitly states that it may contain forward-looking statements based on beliefs and opinions as of the call date. No unpublished price sensitive information (UPSI) was indicated to be shared during the call.

The transcript contained detailed financial data including revenue breakdowns, margin figures, debt position, and capex numbers for Q1 FY27. Management provided specific guidance numbers for FY27 growth targets and explained the impact of new business expenses on current profitability.